Gov. Shapiro proposes $5M to help people with disabilities find, retain employment
The walk, held at the department's Hiram G. Andrews Center, was meant to support and empower Pennsylvanians with disabilities. In an effort to continue the support, Governor Josh Shapiro's proposed 2025-2026 budget calls for an additional $5 million investment in L&I's Office of Vocational Rehabilitation (OVR).
'At L&I, we're not just raising awareness – we're transforming lives by breaking down barriers for Pennsylvanians with autism and other disabilities,' Jill Moriconi, Director of the Commonwealth Technical Institute at HGAC, said. 'Through our work at HGAC, we're creating pathways to independence and meaningful careers where every person is supported and celebrated. Governor Shapiro's proposed investments in vocational rehabilitation reflect our commitment to building a Commonwealth where disability is not recognized as a limitation, but as a powerful source of innovation, resilience, and strength for our communities and our economy.'
In addition to the proposed $5 million for OVR, some other key proposed investments are:
$1 million to the Centers for Independent Living (CIL) to recruit and hire staff
$5 million to support workforce initiatives to educate, train, and recruit nursing professionals
$12.5 million dedicated to the Workforce and Economic Development Network appropriation, leveraging $10 million in existing funds and $2.5 million in new state funds to train additional workers
$10 million to further boost employment in the behavioral health sector by expanding the Primary Care Loan Repayment Program at the Department of Health (DOH), broadening the program's geographic eligibility requirements and making it available to behavioral health care workers in all regions of Pennsylvania and
$55 million to support childcare workforce recruitment and retention grants; this would provide roughly $1,000 more annually per employee to licensed childcare centers in the Child Care Works program.
Currently, the budget has yet to be approved.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on LinkedIn.
Axios
4 days ago
- Axios
States sue Trump admin over trans care access
Sixteen states and the District of Columbia are suing the Trump administration over what they charge is a coordinated federal effort to intimidate health care providers into stopping gender-affirming care for individuals under age 19. The big picture: The suit revolved around a January executive order President Trump issued and subsequent administration actions the states say amount to an attempt to enforce a nationwide ban on transition-related care. The latest: The administration actions are not only denying medically necessary care but coercing hospitals and doctors into violating anti-discrimination and other state laws, according to the complaint. The suit referenced Justice Department guidance threatening criminal prosecution of providers, investigations of hospitals, and demands for patient data. The states asked the court for an injunction, saying the actions were unlawful and intrude on their authority to enforce their own laws. The suit was filed in U.S. District Court in Massachusetts by attorneys general from California, Connecticut, Delaware, the District of Columbia, Hawai'i, Illinois, Maine, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New Mexico, New York, Rhode Island and Wisconsin. Pennsylvania Democratic Gov. Josh Shapiro was also listed as a plaintiff. Between the lines: While courts have temporarily blocked the administration from stripping federal funding from providers of gender-affirming medical services to minors, the Justice Department has taken other steps, including subpoenaing doctors for patient information. Meanwhile, the Federal Trade Commission has launched an inquiry into whether providers are making false claims about gender-affirming care's benefits or not disclosing risks. The efforts have prompted major hospitals to pause or shut down on transition-related services in states where they remain legal. "This reduction in services has caused significant harm to transgender adolescents in the Plaintiff States, depriving them of essential care at a critical time in their development," the states argue in the complaint. What they're saying:"The federal government is running a cruel and targeted harassment campaign against providers who offer lawful, lifesaving care to children," New York Attorney General Letitia James said in a statement. The White House last week claimed credit for making providers halt what it termed "child sexual mutilation," issuing a release listing more than a dozen health systems that stopped providing puberty blockers, hormone therapy and surgeries. "For years, politicians have promised to end the barbaric, pseudoscientific practice — but President Trump is the only one who has actually delivered," it said in a statement. About 40% of transgender youth live in the 27 states that already limit access to gender-affirming care for minors, according to KFF. Of those states, 17 currently face legal challenges to their policies.
CBS News
4 days ago
- CBS News
Gov. Josh Shapiro joins lawsuit suing Trump Administration over gender-affirming care
Pennsylvania Governor Josh Shapiro is joining with other state leaders to sue the Trump Administration over gender-affirming care after the U.S. Department of Justice subpoenaed several healthcare clinics and providers. More than 20 doctors and clinics that have been involved in transgender medical care were subpoenaed, and now Governor Shapiro is joining with 16 other Democratic officials suing the Trump Administration over restrictions for gender-affirming care for people under the age of 19. The federal lawsuit filed in Boston alleges that attempts to deny medically necessary healthcare to transgender people through an executive order are unlawful. According to the Department of Justice, however, these investigations include healthcare fraud, false statements, and more, saying those involved in performing these types of procedures on children will be held accountable. The lawsuit claims the Trump Administration is targeting these individuals, as well as alleging the administration has intimidated healthcare providers. It says this order is unlawful because there is no federal statute that bans providing care to minors. UPMC was among those subpoenaed along with others in Pennsylvania. "These actions have made it abundantly clear that our clinicians can no longer provide certain types of gender-affirming care without risk of criminal prosecution," a UPMC spokesperson told KDKA-TV. "This includes specific restrictions on puberty blockers and hormone therapy for individuals under 19." While it is unknown what will come from the lawsuit, UPMC has said they will continue to provide necessary healthcare within the bounds of the law.
